Andrew Peter Maxted
Research Subjects
Andrew Peter Maxted has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alun Williams
Department of Paediatric Nephrology Nottingham University Hospitals NHS Trust Nottingham UK
2 shared publications- Martin Christian
Department of Paediatric Nephrology, Nottingham Children’s Hospital, Nottingham, UK
2 shared publications Abigail Hill
Paediatric Intensive Care Unit, Nottingham Children’s Hospital, Queens Medical Centre, Nottingham, United Kingdom
1 shared publicationAndrew Lunn
Nottingham Renal and Urology Unit, Nottingham Children's Hospital, QMC, Nottingham, UK
1 shared publication- Andrew Lunn
Department of Paediatric Nephrology Nottingham University Hospitals NHS Trust Nottingham UK
1 shared publication Brian Davies
Nottingham Renal and Urology Unit, Nottingham Children's Hospital, QMC, Nottingham, UK
1 shared publication
Latest Publications
- Open Access
- 3 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14703
Pharmacokinetics of Envarsus in pediatric kidney transplant recipients – phase 1 pilot conversion study
Introduction: Tacrolimus is the standard immunosuppressant for pediatric kidney transplants and is routinely administered twice daily (BD‐tac). Envarsus (LCP‐tac), an extended‐release formulation, is approved for adults but not for pediatric patients.Methods: We conducted a pilot open‐label phase 1 study in stable pediatric kidney transplant recipients (age < 18 at the time of study). Our primary objective was to compare the pharmacokinetics (Pk) of LCP‐tac versus BD‐tac. We conducted two 24‐h Pk studies: pre‐conversion (BD‐tac) and 4 weeks post‐conversion to LCP‐tac. Patients were followed for 6 months, with the option to continue LCP‐tac.Results: Five patients completed the study, with no returns to BD‐tac. Median age was 15 years (range 11–17). LCP‐tac exhibited an extended‐release profile versus the bimodal profile of BD‐tac. Time to maximum concentration was delayed (5 h vs. 1 h), and maximum concentration was lower (9.9 ng/mL vs. 14.4 ng/mL). Tacrolimus area under the curve (24 h) was comparable (141 ± 46.5 ng/mL vs. 164 ± 27.8 ng/mL). No new safety concerns arose. There were no rejection and no difference in eGFR at the study's end (1.5 mL/min/1.73 m2, range − 1.7 to 2.3 mL/min/1.73 m2). Concentration/dose ratio was higher in LCP‐tac (1.8 ± 0.64 vs. 0.8 ± 0.39). The final conversion ratio was 0.6 (BD‐tac: LCP‐tac).Conclusion: Our pilot study confirms the extended‐release Pk profile and improved absorption of LCP‐tac compared to BD‐tac. A larger study is needed to further evaluate the population Pk characteristics in children.
- 3 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14703
Open AccessPharmacokinetics of Envarsus in pediatric kidney transplant recipients – phase 1 pilot conversion study
Introduction: Tacrolimus is the standard immunosuppressant for pediatric kidney transplants and is routinely administered twice daily (BD‐tac). Envarsus (LCP‐tac), an extended‐release formulation, is approved for adults but not for pediatric patients.Methods: We conducted a pilot open‐label phase 1 study in stable pediatric kidney transplant recipients (age < 18 at the time of study). Our primary objective was to compare the pharmacokinetics (Pk) of LCP‐tac versus BD‐tac. We conducted two 24‐h Pk studies: pre‐conversion (BD‐tac) and 4 weeks post‐conversion to LCP‐tac. Patients were followed for 6 months, with the option to continue LCP‐tac.Results: Five patients completed the study, with no returns to BD‐tac. Median age was 15 years (range 11–17). LCP‐tac exhibited an extended‐release profile versus the bimodal profile of BD‐tac. Time to maximum concentration was delayed (5 h vs. 1 h), and maximum concentration was lower (9.9 ng/mL vs. 14.4 ng/mL). Tacrolimus area under the curve (24 h) was comparable (141 ± 46.5 ng/mL vs. 164 ± 27.8 ng/mL). No new safety concerns arose. There were no rejection and no difference in eGFR at the study's end (1.5 mL/min/1.73 m2, range − 1.7 to 2.3 mL/min/1.73 m2). Concentration/dose ratio was higher in LCP‐tac (1.8 ± 0.64 vs. 0.8 ± 0.39). The final conversion ratio was 0.6 (BD‐tac: LCP‐tac).Conclusion: Our pilot study confirms the extended‐release Pk profile and improved absorption of LCP‐tac compared to BD‐tac. A larger study is needed to further evaluate the population Pk characteristics in children.
- 24 February 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (6) , 1425
Correction to: Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome
- 24 February 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (6) , 1425
Correction to: Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome
- 20 February 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (1) , 37-47
Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome
The use of corticosteroids in the treatment of steroid-sensitive nephrotic (SSNS) syndrome in children has evolved surprisingly slowly since the ISKDC consensus over 50 years ago. From a move towards longer courses of corticosteroid to treat the first episode in the 1990s and 2000s, more recent large, well-designed randomized controlled trials (RCTs) have unequivocally shown no benefit from an extended course, although doubt remains whether this applies across all age groups. With regard to prevention of relapses, daily ultra-low-dose prednisolone has recently been shown to be more effective than low-dose alternate-day prednisolone. Daily low-dose prednisolone for a week at the time of acute viral infection seems to be effective in the prevention of relapses but the results of a larger RCT are awaited. Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective. The need for large RCTs to address the question of whether corticosteroid doses can be reduced was the conclusion of the authors of the recent corticosteroid therapy for nephrotic syndrome in children Cochrane update. This review summarizes development in thinking on corticosteroid use in SSNS and makes suggestions for areas that merit further scrutiny.
- 20 February 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (1) , 37-47
Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome
The use of corticosteroids in the treatment of steroid-sensitive nephrotic (SSNS) syndrome in children has evolved surprisingly slowly since the ISKDC consensus over 50 years ago. From a move towards longer courses of corticosteroid to treat the first episode in the 1990s and 2000s, more recent large, well-designed randomized controlled trials (RCTs) have unequivocally shown no benefit from an extended course, although doubt remains whether this applies across all age groups. With regard to prevention of relapses, daily ultra-low-dose prednisolone has recently been shown to be more effective than low-dose alternate-day prednisolone. Daily low-dose prednisolone for a week at the time of acute viral infection seems to be effective in the prevention of relapses but the results of a larger RCT are awaited. Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective. The need for large RCTs to address the question of whether corticosteroid doses can be reduced was the conclusion of the authors of the recent corticosteroid therapy for nephrotic syndrome in children Cochrane update. This review summarizes development in thinking on corticosteroid use in SSNS and makes suggestions for areas that merit further scrutiny.
- 1 December 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (6) , 102928
Double filtration plasmapheresis – 10-year pediatric experience as an alternative to plasma exchange
- 1 December 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (6) , 102928
Double filtration plasmapheresis – 10-year pediatric experience as an alternative to plasma exchange
- 1 November 2017
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 37 (6) , 650-651
Peritoneal Dialysis Catheter Removal Post-Transplant — A Rare Case of Delayed Bowel Perforation
Peritoneal dialysis (PD) is a well-established form of renal replacement therapy and the practice of leaving catheters in situ post-transplantation widely accepted. We present a rare complication: a child presenting with anal protrusion of the PD catheter.
- 1 November 2017
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 37 (6) , 650-651
Peritoneal Dialysis Catheter Removal Post-Transplant — A Rare Case of Delayed Bowel Perforation
Peritoneal dialysis (PD) is a well-established form of renal replacement therapy and the practice of leaving catheters in situ post-transplantation widely accepted. We present a rare complication: a child presenting with anal protrusion of the PD catheter.
- 1 February 2013
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 131 (2) , e626-e628
Oral Sildenafil as a Rescue Therapy in Presumed Acute Pulmonary Hypertensive Crisis
A 23-week-old baby, born at 26+2 weeks, presented to the hospital with critical respiratory failure, which was impossible to stabilize. She had unstable oxygen saturations between 35% and 95%. A presumptive diagnosis of bronchopulmonary dysplasia with associated pulmonary hypertensive crisis was made. In the absence of inhaled nitric oxide, 2 oral doses of 1 mg/kg sildenafil were given, with a dramatic improvement 30 to 45 minutes later. Her oxygenation index fell from 43 to 14. She made a full recovery and was discharged from the hospital 2 weeks later.
- 1 February 2013
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 131 (2) , e626-e628
Oral Sildenafil as a Rescue Therapy in Presumed Acute Pulmonary Hypertensive Crisis
A 23-week-old baby, born at 26+2 weeks, presented to the hospital with critical respiratory failure, which was impossible to stabilize. She had unstable oxygen saturations between 35% and 95%. A presumptive diagnosis of bronchopulmonary dysplasia with associated pulmonary hypertensive crisis was made. In the absence of inhaled nitric oxide, 2 oral doses of 1 mg/kg sildenafil were given, with a dramatic improvement 30 to 45 minutes later. Her oxygenation index fell from 43 to 14. She made a full recovery and was discharged from the hospital 2 weeks later.